THANK YOU FOR SUBSCRIBING
AI in drug discovery and development helps increase efficiency and decrease the expense of the process.
FREMONT, CA : Artificial intelligence (AI) has recently become a popular subject in the medical care industry. AI is the science of developing machines that can perform tasks similar to those performed by humans. AI has a lot of potentials to benefit humanity. In today's world, the medical care industry, especially the pharmaceutical industry, is in a lot of trouble.
Traditional drug discovery is a time-consuming, expensive, and inefficient method. It will cost about 2.6 USD and take an average of 12 years to complete. By combining the medical care industry (particularly the pharmaceutical industry) with artificial intelligence, companies can save money, time, and effort. Biopharmaceutical firms are attempting to partner with AI-based firms. Drug discovery and development processes are now a priority for AI-based businesses.
Recent developments in high-performance computing, as well as the availability of massive, annotated data sets and new architectures for integrating deep neural networks (DNNs), have accelerated the field to unparalleled levels. In image, speech, and text recognition, autonomous driving, and various other tasks, DNNs have outperformed humans. The use of artificial intelligence (AI) is urgently needed.
Process of Drug Development
There are several steps involved in the manufacture of every drug. The first step in drug production is to identify a molecular target for disease. Target identification aims to identify a gene or protein that plays a vital role in the disease.
The words "hit" and "lead" are both critical terms in the drug development process. The first compound to demonstrate action against a biological target is referred to as a hit. Hit expansion is the method of recognizing compounds extracted from a hit. The next step in drug production is to find a lead. Lead is another chemical element that is thought to be capable of treating the disease.
Following the identification of a drug candidate, pre-clinical research is conducted to assess efficacy and safety.
Scientists decide ADME, mechanism of action, best dosage, administration route, effects on gender, interactions with other medications, side effects, effects on gender, and other factors during pre-clinical testing.
Researchers then move on to clinical drug production after completing pre-clinical research. Clinical experiments and human participant research are included. Clinical studies are used to gather information about the effectiveness and safety of treatments. Clinical trials are carried out in three stages, Phase 1, Phase 2, and Phase 3.
FDA approves it after phase III trials because it shows efficacy, safety, and acceptable results according to FDA guidelines.
Post Marketing Surveillance
After they have been approved, manufactured, and marketed, the process of monitoring the safety of drugs is known as post-marketing surveillance. Post-marketing monitoring reports are sent to the FDA's adverse reporting system (FEARS) database.